THALOMID (THALIDOMIDE)
- Multiple myeloma
- Erythema nodosum leprosum
- Prevent recurrence of cutaneous ENL lesions
100 mg capsule
- 1 capsule (100 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
150 mg capsule
- 2 capsules (300 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
200 mg capsule
- 1 capsule (200 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
50 mg capsule
- 1 capsule (50 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
Erythema nodosum leprosum
- 2 capsules (100 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
- 1 capsule (100 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
- 1 capsule (100 mg) by oral route 2 times per day at least 1 hourafter meals
- 2 capsules (200 mg) by oral route 2 times per day at least 1 hour after meals
- 1 capsule (200 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
- 2 capsules (200 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
- 4 capsules (200 mg) by oral route 2 times per day at least 1 hour after meals
- 1 capsule (200 mg) by oral route 2 times per day at least 1 hourafter meals
- 2 capsules (300 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
- 3 capsules (300 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
- 6 capsules (300 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
- 8 capsules (400 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
- 2 capsules (400 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
Multiple myeloma
- 1 capsule (200 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
- 2 capsules (200 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
Prevent recurrence of cutaneous ENL lesions
- 1 capsule (50 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
- 2 capsules (100 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
- 1 capsule (100 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
- 1 capsule (100 mg) by oral route 2 times per day at least 1 hourafter meals
- 2 capsules (200 mg) by oral route 2 times per day at least 1 hour after meals
- 1 capsule (200 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
- 2 capsules (200 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
- 1 capsule (200 mg) by oral route 2 times per day at least 1 hourafter meals
- 2 capsules (300 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
- 4 capsules (400 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
- 2 capsules (400 mg) by oral route once daily at bedtime and at least 1 hour after the evening meal
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- None
Severe
Moderate
- None
- Lactating mother
- Posterior reversible encephalopathy syndrome
- Pregnancy
Contraindicated
- Bradycardia
- Cerebrovascular accident
- Deep venous thrombosis
- Myocardial ischemia
- Neutropenic disorder
- Peripheral neuropathy
- Pulmonary thromboembolism
- Thromboembolic disorder
Severe
Moderate
- Acute myeloid leukemia
- HIV infection
- Lower seizure threshold
- Myelodysplastic syndrome
- Orthostatic hypotension
- Seizure disorder
- Thrombocytopenic disorder
THALOMID (THALIDOMIDE)
- Multiple myeloma
- Erythema nodosum leprosum
- Prevent recurrence of cutaneous ENL lesions
- Dyspnea
- Hypocalcemia
- Leukopenia
- Peripheral motor neuropathy
- Peripheral neuropathy
- Thromboembolic disorder
- Acute confusion
- Constipation
- Dizziness
- Drowsy
- Dry skin
- Edema
- Fatigue
- Fever
- General weakness
- Headache disorder
- Muscle weakness
- Nausea
- Skin rash
- Symptoms of anxiety
- Tremor
- Weight gain
- Weight loss
More Frequent
Severe
Less Severe
- Acute abdominal pain
- Hyperbilirubinemia
- Infection
- Oral candidiasis
- Agitation
- Anorexia
- Arthralgias
- Diarrhea
- Increased appetite
- Mood changes
- Myalgias
- Orthostatic hypotension
- Swelling of ankles or feet
- Xerostomia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal ECG
- Acute myocardial infarction
- Anaphylaxis
- Angioedema
- Apnea
- Arterial thrombosis
- Biliary obstruction
- Bradycardia
- Cardiac arrhythmia
- Cerebrovascular accident
- Chemotherapy-induced hyperuricemia
- Chronic myelocytic leukemia
- Cytomegalovirus disease
- Deep venous thrombosis
- DRESS syndrome
- Erythema multiforme
- Erythema nodosum
- Exfoliative dermatitis
- Gastrointestinal hemorrhage
- Gastrointestinal obstruction
- Gastrointestinal perforation
- Hearing loss
- Herpes zoster
- Hypersensitivity drug reaction
- Hypotension
- Hypothyroidism
- Lymphopenia
- Neutropenic disorder
- Pancytopenia
- Pleural effusions
- Posterior reversible encephalopathy syndrome
- Pulmonary hypertension
- Pulmonary thromboembolism
- Reactivation of hepatitis B
- Renal failure
- Seizure disorder
- Septic shock
- Sick sinus syndrome
- Stevens-johnson syndrome
- Suicidal
- Syncope
- Thrombocytopenic disorder
- Toxic epidermal necrolysis
- Transient cerebral ischemia
Less Severe
- Amenorrhea
- Aphthous stomatitis
- Blurred vision
- Conjunctivitis
- Cramps in legs
- Depression
- Diplopia
- Dysgeusia
- Flu-like symptoms
- Galactorrhea not associated with childbirth
- Lymphedema
- Nail disorders
- Nystagmus
- Oliguria
- Raynaud's phenomenon
- Sedation hangover effect
- Urinary incontinence
- Urticaria
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Thalidomide
Safety and efficacy not established in children age less than 12 years.
- 1 Day – 12 Years
- Safety and efficacy not established in children age less than 12 years.
Thalidomide
- Severity Level:
1
- Additional Notes: Fetal anomalies reported, contraindicated during any stage of pregnancy.
Contraindicated
Thalidomide
Potential serious adv eff on infant;Moleculr wt low enough for poss excretion
General | Excretion Potential | Effect on Infant | Notes |
Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Potential serious adv eff on infant;Moleculr wt low enough for poss excretion |
Precaution Exists
None
General | Excretion Potential | Effect on Infant | Notes |
None |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
Thalidomide
General-Higher incidences of atrial fibrillation, constipation, fatigue, nausea, hypokalemia, deep venous thrombosis, hyperglycemia, pulmonary embolism, and asthenia in the elderly.
Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
Increased Risk / Adverse Effects | N | N | Y | Y | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- Women who are pregnant must not use thalidomide. Women must avoid becoming pregnant while taking this medication. Even a single dose of thalidomide has caused severe (often fatal) birth defects when used during pregnancy.<br /><br />You must have 2 negative pregnancy tests before you start treatment with thalidomide (within 10 to 14 days before and 24 hours before starting), repeating the test at least monthly. Do not start or continue thalidomide treatment unless you have a negative pregnancy test result. Female patients must use 2 effective forms of birth control (or completely avoid sexual intercourse) for 1 month before starting thalidomide, during use, and for 1 month after stopping this drug.<br /><br />Talk to your doctor about reliable birth control choices. If your period is late, or if you have sexual intercourse at any time without using 2 effective forms of birth control, stop taking this medication and contact your doctor right away. (See also Precautions section.) Because thalidomide also passes into semen, men who use this drug and have sex with women must use a latex condom during all sexual contact, even if they have had a vasectomy.<br /><br />Continue using condoms and other birth control as directed until 1 month after thalidomide treatment has been stopped. Only patients who have signed an informed consent and agree to the requirements of the REMS program may obtain and use thalidomide. Only physicians enrolled in REMS may prescribe thalidomide, and only pharmacies enrolled in the program may dispense it.<br /><br />Consult your doctor or pharmacist for more details about the REMS program and for more information about the risks and benefits of using this medication. These requirements apply in the United States. If you live in Canada or any other country, consult your doctor and pharmacist for your country's regulations.<br /><br /> When used to treat a certain type of cancer (multiple myeloma), thalidomide can increase the risk of serious blood clots in the legs or lungs, as well as heart attacks and strokes. Seek immediate medical attention if you develop shortness of breath, chest pain, jaw/neck/left arm pain, weakness on one side of your body, slurred speech, sudden vision changes, or arm/leg swelling. While you are taking thalidomide, your doctor may also direct you to take aspirin or other "blood thinners" (e.g., warfarin) to lessen the risk of these types of blood clots.<br /><br />Talk to your doctor for more information, and tell him/her if you have diabetes, high blood pressure or high cholesterol, kidney problems, or if you smoke. (See also Side Effects section.)
Erythema nodosum leprosum | |
A30.5 | Lepromatous leprosy |
Multiple myeloma | |
C90.0 | Multiple myeloma |
C90.00 | Multiple myeloma not having achieved remission |
C90.02 | Multiple myeloma in relapse |
Prevent recurrence of cutaneous ENL lesions | |
A30.5 | Lepromatous leprosy |
0-9 | A-Z |
---|---|
A30.5 | Lepromatous leprosy |
A30.5 | Lepromatous leprosy |
C90.0 | Multiple myeloma |
C90.00 | Multiple myeloma not having achieved remission |
C90.02 | Multiple myeloma in relapse |